monomethylauristatin-f and Multiple-Myeloma

Belantamab mafodotin (BLENREP

Topics: Adult; Animals; Antibodies, Monoclonal, Humanized; B-Cell Maturation Antigen; Cell Line, Tumor; Clinical Trials as Topic; Disease Progression; Drug Approval; Drug Resistance, Neoplasm; Humans; Immunoconjugates; Infusions, Intravenous; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Oligopeptides; Progression-Free Survival; Tubulin Modulators; Xenograft Model Antitumor Assays

Novel effective immunotherapies are needed for patients with multiple myeloma (MM), since disease recurrence remains a major obstacle. B-cell maturation antigen (BCMA), a cell surface protein universally expressed on malignant plasma cells , has emerged as a very selective antigen to be targeted in novel treatments for MM. We here first review BCMA-related biology, and then highlight the recent clinical development of a novel afucosylated anti-BCMA monoclonal antibody conjugated with monomethyl auristatin F via noncleavable linker (GSK2857916). Chimeric antigen receptor-expressing T cells targeting BCMA may also induce specific and durable anti-MM responses by patients' own effector cells. Clinical trials testing these two approaches (NCT02064387, NCT02215967) are currently ongoing in relapsed and refractory MM patients.

Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; B-Cell Maturation Antigen; Clinical Trials as Topic; Humans; Immunotherapy; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Protein Engineering; Receptors, Antigen, T-Cell; Recombinant Fusion Proteins; T-Lymphocytes